

Reading Materials

GLP-1 and GIP Agonists

FDA and Safety

1. US Food and Drug Administration. Certain Type of Medicines Approved for Type 2 Diabetes and Obesity: Drug Safety Communication - Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions. Preliminary evaluation does not suggest a causal link. [January 2024](#).
2. US Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. [December 2023](#).

HFpEF

3. Achanta A, Belak L, Ritchie CS, et al. Age-Related Usage of GLP-1 Agonists in Obese Patients With Heart Failure and Preserved Ejection Fraction. *J Am Coll Cardiol*. 2024;83:1348-1350. <https://doi.org/10.1016/j.jacc.2024.01.033>
4. Butler J, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. *J Am Coll Cardiol*. 2023;82:2087-2096. <https://doi.org/10.1016/j.jacc.2023.09.811>
5. Kittleson MM, Panjra GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2023;81:1835-1878. <https://www.jacc.org/doi/10.1016/j.jacc.2023.03.393>
6. Kosiborod MN, Verma S, Borlaug BA, et al. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. *Circulation*. 2024;149:204-216. <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067505>
7. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2023;389:1069-1084. <https://www.nejm.org/doi/full/10.1056/NEJMoa2306963>
8. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. *N Engl J Med*. 2024. <https://www.nejm.org/doi/full/10.1056/NEJMoa2313917>

Non-Alcoholic Fatty Liver Disease

9. Nevola R, Epifani R, Imbriani S, et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. *Int J Mol Sci*. 2023;24. <https://www.mdpi.com/1422-0067/24/2/1703>

Obesity

10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022;387:205-216. <https://www.nejm.org/doi/full/10.1056/NEJMoa2206038>
11. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023;389:2221-2232. <https://www.nejm.org/doi/full/10.1056/NEJMoa2307563>
12. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021;384:989-1002. <https://www.nejm.org/doi/10.1056/NEJMoa2032183>
13. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metab*. 2022;24:1553-1564. <https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14725>

Obesity Diagnosis and Overview

14. ACC CardioSmart. What is Obesity infographic. <https://www.cardiosmart.org/topics/healthy-living/lose-weight/obesity-and-heart-disease>
15. BurrIDGE K, Christensen SM, Golden A, et al. Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;1:100007. <https://www.sciencedirect.com/science/article/pii/S2667368121000073?via%3Dihub>

Obesity Treatment

16. Anderson J, Kushner R, Miller E, et al. Overweight and Obesity Management for Primary Care Clinicians: Executive Summary. *Clin Diabetes*. 2022;41:85-89. <https://diabetesjournals.org/clinical/article/41/1/85/147681/Overweight-and-Obesity-Management-for-Primary-Care>
17. Gasoyan H, Pfoh ER, Schulte R, et al. Early- and later-stage persistence with antiobesity medications: A retrospective cohort study. *Obesity (Silver Spring)*. 2024;32:486-493. <https://onlinelibrary.wiley.com/doi/10.1002/oby.23952>
18. Maki KC, Kirkpatrick CF, Allison DB, Gadde KM. Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction. *Expert Rev Endocrinol Metab*. 2023;18:307-319. <https://www.tandfonline.com/doi/full/10.1080/17446651.2023.2209176>
19. Harrington J, Felker GM, Januzzi JL, et al. Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions. *Curr Cardiol Rep*. 2024;26:61-71. <https://link.springer.com/article/10.1007/s11886-023-02016-z>
20. Mentias A, Desai MY, Aminian A, et al. Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity. *Circ Heart Fail*. 2024;17:e010453. <https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.010453>